Woodline Partners LP Supernus Pharmaceuticals, Inc. Transaction History
Woodline Partners LP
- $17.6 Billion
- Q2 2025
A detailed history of Woodline Partners LP transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 772,976 shares of SUPN stock, worth $31.9 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
772,976Holding current value
$31.9 Million% of portfolio
0.14%Shares
10 transactions
Others Institutions Holding SUPN
# of Institutions
311Shares Held
61.6MCall Options Held
11.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$429 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$256 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$198 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$125 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$114 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.21B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...